Menu
Innovation for Good Health
Fosun Pharma USA Inc. is led by a team of highly experienced executives with strong track records from leading US and European pharmaceutical companies both in commercial operations and R&D.
104 Carnegie Center, Suite 204
Princeton, NJ 08540
(609) 250-2802
[email protected]
Customer Service & Adverse Event/ Quality Concerns: (855) 282-4882 or [email protected]
© 2023 Fosun Pharma USA Inc. All rights reserved.
Rong Yang is the chief executive officer of Fosun Pharma USA and the senior vice president of Fosun Pharma. He is responsible for expanding Fosun Pharma’s presence in the U.S., driving overall business and organizational growth and representing the company in front of external stakeholders.
Prior to Fosun Pharma, Rong was with Bayer Group for nearly 20 years in a variety of senior positions across United States and Europe. As Vice President he headed Bayer’s U.S. Specialty and Hematology sales and marketing team; he also served as Head of Business Insight and Analytics and was a member of Bayer’s Executive Committee in the United States; as Vice President of Strategy and Finance he oversaw Bayer pharmaceuticals Americas P&L across the U.S., Canada and Latin America with more than 5 billion USD revenue and more than 30 legal entities across the continent. Before moving to the U.S., he was Bayer Pharma’s Country Group General Manager for Czech Republic and Slovakia based in Prague, Czech Republic. Earlier in his career he took various portfolio and commercial roles in Germany and Austria. Rong has lived and worked in five different countries across three continents. Currently he also serves as Board Director of Nature Sunshine, a NASDAQ listed company.
Rong holds a Bachelor of Arts in German and in Economics from Beijing Foreign Studies University and an MBA from Harvard University.
Outside of work, Rong likes family time with his wife Vesna and daughter Zarja. He enjoys hiking, reading and watching soccer games.
Updated 10.2023
Lawrence Brown serves as the head of legal for Fosun Pharma USA. He is responsible for all legal and compliance affairs and activities for Fosun Pharma USA, including all litigation strategy and management; intellectual property prosecution, registration and enforcement; contract drafting, negotiation, compliance and review; corporate ethics, enforcement and policy; corporate governance; and compliance and enterprise risk management. Larry also serves as a key legal business partner and drives critical business decisions.
Prior to joining us, Larry was vice president and assistant general counsel, Intellectual Property (IP) – Generics at Endo Pharmaceuticals/Par Pharmaceutical (Endo/Par). He spent 15 years at Endo/Par in positions of increasing responsibility, overseeing patent litigation strategy, IP prosecution and management, licensing transactions, regulatory law, and antitrust. Prior to joining Endo/Par, Larry had been an associate attorney and patent agent at law firms in Boston and New York.
Larry holds a J.D. from Fordham University School of Law, a PhD in molecular biology from Princeton University, and a bachelor’s degree in Biochemical Sciences from Harvard University. He is admitted to the state bars of New Jersey, New York, and Massachusetts, and the bars of the U.S. Patent and Trademark Office, the Court of Appeals for the Federal Circuit, and the U.S. District Court for the District of New Jersey.
Outside of work, Larry is married with a daughter who is a college senior. He enjoys composing music, painting, photography, creative writing, reading, book collecting, and boating.
Updated 10.2023
Dr. Lawrence Brown serves as Associate General Counsel, Head of Legal (Fusion BioVenture) with responsibility for all aspects of the business unit’s legal affairs. He has over 20 years of experience providing advice and shaping strategies relevant to all aspects of intellectual property, litigation, commercial transactional, commercial risk, pharmaceutical regulatory, and pharmaceutical antitrust issues. Prior to joining Fusion, Larry served as Vice President and Assistant General Counsel, IP – Generics at Endo International/Par Pharmaceutical for 15 years. Before his years in-house, Larry had worked in IP litigation, IP prosecution, and biotechnology/pharmaceutical transactions at law firms in both New York City and Boston. Further, prior to his career transition to law, Larry was a postdoctoral fellow in the Biomedical Engineering Department of Boston University, continuing at that institution his graduate work in computational biophysics and molecular modeling, with a focus on protein-nucleic acid/protein-protein free energy computations, docking, molecular mechanics, and threading.
Dr. Brown holds an A.B. in Biochemical Sciences from Harvard University, a Ph.D. in molecular biology from Princeton University, and a J.D. from the Fordham University School of Law. He is admitted to the bar in New York, New Jersey, and Massachusetts as well as the United States Patent and Trademark Office, U.S. District Court for the District of New Jersey, and the Court of Appeals for the Federal Circuit. Given his scientific and legal backgrounds, Larry enjoys being at the intersection of the two, asking the “what ifs” and “why nots”, questions that are salient to Fusion’s pursuits on the cutting edge of new biotechnological solutions.
Lucia V. Allen Chau is the director of public relations & communications at Fosun Pharma USA. Lucia’s responsibilities include building the company’s presence externally for key events, in alignment with corporate brand strategy.
Prior to joining Fosun Pharma USA, Lucia was director, global corporate affairs, CVRM at AstraZeneca, where she developed and executed global communications plans. Lucia has also advised and led strategic communications in-house at several leading patient advocacy groups, such as the American Heart Association, American Association for Cancer Research, and American Gastroenterological Association, as well as within government agencies like the National Cancer Institute/National Institutes of Health.
During her time as an account lead at several global healthcare agencies, Lucia led the corporate health and executive communications work for Fortune 1 and Fortune 50 companies and supported a range of multinational biotech and biopharma clients across several therapeutic areas. Her experience includes IPOs, executive visibility/thought leadership, medical congresses, awareness campaigns, and branded and unbranded communications for patients and HCPs, for both regulatory milestones and product launches or approvals.
Lucia’s past clients include Walmart Health & Wellness, Humana, Synchrony Bank/CareCredit, Eli Lilly, Sanofi Oncology, Bristol Myers Squibb, Janssen, Astellas, Pfizer, CureVac, Accent Therapeutics, and Karuna Therapeutics.
Lucia holds a Master of Arts in Public Relations from Rowan University and a Bachelor of Arts in English and in Journalism from Northeastern University.
Outside of work, Lucia enjoys spending time with her loved ones and staying active through pickleball and soccer, or fitness classes like Pure Barre.
Updated 10.2023
Rich Greene serves as interim general manager (GM) for In Vitro Diagnostics (IVD) at Fosun Pharma USA. In his current role, he is responsible for overseeing all facets of establishing Fosun as a leading IVD company in the U.S.
Rich has spent 30 years in healthcare with a majority of the years within branded and generic pharmaceutical companies. He started his healthcare career as a sales representative and advanced through a diverse range of responsibilities in sales management and corporate accounts, including managed care, wholesalers, retail pharmacies, GPOs, IDN’s and compounders. Rich has held key leadership positions with companies such as Organon, PDL BioPharma, TherRx, Avadel and Provepharm. Rich has always been drawn to smaller companies where he played instrumental roles, with very diverse and open-ended opportunities for growth.
Rich holds a Bachelor of Arts in Business Administration and Computer Science, with minors in Accounting and Economics.
Rich is married to his wife Sheryl and has two adult children. In his free time, Rich enjoys spending time outdoors engaged in activities such as hiking and biking. Other activities include concerts, sporting events, travel, and spending time with family/friends.
Updated 10.2023
Stan Lechpammer serves as the vice president of Medical Affairs, Innovative Medicines at Fosun Pharma USA. He is responsible for the strategy and operations of Medical Affairs, executing a comprehensive pre-launch readiness plan to secure early adoption of serplulimab by U.S. oncologists. Stan also coordinates Medical Affairs activities with Henlius to support the ASTRIDE trial.
Prior to joining us, Stan was vice president, Medical Affairs at ImmunityBio, where he built their complete Medical Affairs capabilities in support of the organization’s first launch in the U.S. Stan has over 17 years of experience in the biotech industry and has served in positions of increasing responsibility in Medical Affairs and Clinical Development at Amgen / Onyx, Genzyme, EMD Serono, Jazz Pharmaceuticals, Medivation / Pfizer, and GSK. He participated in bringing to the market several novel oncology drugs, including NDA and sNDA launches to post-launch development in the US and ROW (Vectibix®, Nexavar®, Campath®, Defitelio®, Talzenna®, Xtandi®, and Zejula®).
Stan obtained his MD and Ph.D. from the University of Zagreb, School of Medicine in the EU and completed his post-doctoral fellowship in Radiation Oncology/Nuclear Medicine at Harvard Medical School and additional fellowships at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.
Stan is married to his wife Mirna and has two children, Laura and Eric. In his free time, he enjoys hiking, kayaking, and hearty BBQ.
Updated 10.23.2023
Annah Litzenberger serves as Chief Human Resources Officer (CHRO) of Fosun Pharma USA. As the CHRO, she is responsible for the People Strategy that balances employees’ needs with the company’s interests. She is a strategic partner that enables the business to achieve their goals through innovation and an entrepreneurial mindset. She and her team ensure that the company has the talent, culture and commitment necessary to meet its strategic plans for growth, and the leadership necessary to achieve its global objectives.
Prior to joining us, Annah was the vice president, head of HR at Xilio Therapeutics. Prior to that, she was GSK’s global head of talent and inclusion & diversity for Pharma R&D. She joined GSK through the acquisition of TESARO, where she was the head of HR. Before entering the biotech/pharma industry, Annah spent over 15 years at Santander Bank in a range of HR roles of increasing responsibility, most recently serving as senior vice president, head of learning and organizational development.
Annah holds a Bachelor of Science in Criminal Justice, with minors in Psychology and Political Science from Kutztown University of Pennsylvania.
Annah is married to her husband, Mike. They have 2 daughters, Olivia and Mackenzie, and pets Leroy and Charli. They are Disney fanatics and escape to the most MAGICAL place on earth each year. When not at work or Disney, Annah loves being at the gym, spending time with family and friends, and being anywhere warm and sunny!
Updated 10.2023
Ahmad-Reza Saadat serves as vice president, business development, Innovative Medicines for Fosun Pharma USA. In his current role, he is responsible for licensing, partnering, strategic investments, and M&A.
Ahmad has over 25 years of experience in the pharmaceutical industry, including R&D, business development, corporate strategy, program and portfolio management, and drug commercialization. He has negotiated and executed strategic partnerships, licensing agreements and acquisitions, as well as contributed to capital raises at Momenta, Epizyme and Elpis and drug commercialization at Sarepta. Ahmad also has 10 years of drug discovery experience as a research scientist at Abbvie, Vertex, and Chiron.
Ahmad holds an MBA from F.W. Olin Graduate School of Business at Babson College, a Master of Science in Pharmacology from Northeastern University, and a Bachelor of Science in Chemistry from the University of Massachusetts.
Updated 10.2023
Mousumi Sannigrahi is the chief commercial officer of Innovative Medicines at Fosun Pharma USA. She is responsible for building out the commercial team, setting up the operating infrastructure, and managing the collaboration with Henlius for Innovative Medicines. Mousumi is a seasoned leader whose experience spans product innovation and commercialization.
Prior to joining us, she served as the U.S. Head of CSU, Immunology at Novartis. At Novartis, Mousumi held different global and U.S. leadership roles in strategy, sales, marketing, and business. Before that, Mousumi was with LEK Consulting, responsible for commercial, pipeline, and investment strategies for pharma, biotech, and private equity firms. At Dainippon Sumitomo Pharma, she was part of successful launches including the blockbuster Latuda ®. She started her career at Schering Plough in R&D as a medicinal chemist in Infectious Diseases and Oncology. She is passionate about leading and building high-performing teams and bringing new innovations to patients.
Mousumi holds a Ph.D. in Organic Chemistry from the University of Alberta and an MBA from Duke University.
Outside of work, Mousumi enjoys the outdoors, art, and learning about new cultures.
Updated 10.2023
Jeremy Tatum serves as chief commercial officer and general manager (GM), Established Medicines for Fosun Pharma USA, and is on the Board of Directors for Novelstar Pharmaceuticals. He was initially hired as vice president of Commercial Operations and was later promoted to the Interim CEO and GM of Fosun Pharma USA. In his current role, he is responsible for all commercial operations, strategy, and development of the Established Medicines business unit in the U.S.
Jeremy has spent 29 years in healthcare, medical devices, and pharma (brand and generics). Jeremy’s leadership has shaped the commercial strategies and portfolios of companies like Merck, Cubist, Auromedics (a division of Aurobindo), and American Regent.
Jeremy holds a Bachelor of Arts in Business Psychology from the University of Arkansas at Little Rock and a Master of Arts in Health Services Administration-Informatics from the University of Phoenix.
Outside of work, Jeremy likes to work out, travel, and build anything from motorcycles to houses.
Updated 10.2023
Aileen Wang is the chief financial officer of Fosun Pharma USA. Aileen’s responsibilities include leading the Finance team on activities such as budgeting, financial analysis, corporate controllership, day-to-day operations, process integration or improvement, capital markets, and investor relationships. Aileen also serves as a key finance business partner and drives critical business decisions.
Prior to joining Fosun Pharma USA, Aileen was the chief financial officer of Clover BioPharma (HKEx 02197), supporting the company from a series-C and clinical-stage biotech company to a publicly listed and commercial-stage company. Before that, Aileen worked in Novartis for over 10 years with five job rotations and had increasing leadership responsibilities in both the U.S. and China.
Aileen holds an MBA from Pennsylvania State University and a bachelor’s degree in Engineering from Shanghai Jiaotong University. She is an Illinois-registered certified public accountant (CPA) and a chartered financial analyst (CFA).
Outside of work, Aileen is married with two children (a boy and a girl). She is an animal lover and adopted a mixed-border collie dog. She also enjoys traveling with family.
Updated 10.2023
Dr. Lijun Wu is the Chief Scientific Officer and Founder and head of FUSION BioVenture. She founded FUSION, Fosun Pharma’s innovation incubation platform in the US, which incubated and launched Archimmune Therapeutics and Leverna Therapeutics, where she is the Chair of the Board. She is also the acting CEO of Leverna. Prior to joining Fosun Pharma in 2018, she was an Entrepreneur-in-Residence at Atlas Venture and Senior Vice President of Preclinical and Clinical Development at Delinia. Prior to that, Dr. Wu held various senior leadership positions including Concert Pharmaceuticals (VP), Resolvyx Pharmaceuticals (VP), Novartis Institutes for BioMedical Research (Executive Director), and Millennium Pharmaceuticals (Director).
Dr. Wu is a seasoned executive with >25-years of experience in R&D, investment, and BD in startups established biotech, and large pharmaceutical companies in the US and across borders. She is an author of ~70 peer-reviewed publications, an inventor on a number of patents, and the recipient of Massachusetts High Tech’s “Women to Watch” award. She has been serving on the advisory council of IBBS/Johns Hopkins School of Medicine and is a member of JHU’s Society of Scholars.
Dr. Wu received her Ph.D. in Biochemistry, Molecular Biology, and Cell Biology from Northwestern University and completed a postdoctoral fellowship at Johns Hopkins University School of Medicine.
Updated 10.2023